- Home
- ADPT vs MHD Comparison
ADPT vs MHD Comparison
Compare ADPT & MHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- MHD
- Stock Information
- Founded
- ADPT 2009
- MHD N/A
- Country
- ADPT United States
- MHD United States
- Employees
- ADPT 709
- MHD N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- MHD Investment Bankers/Brokers/Service
- Sector
- ADPT Health Care
- MHD Finance
- Exchange
- ADPT Nasdaq
- MHD Nasdaq
- Market Cap
- ADPT 749.7M
- MHD 632.5M
- IPO Year
- ADPT 2019
- MHD N/A
- Fundamental
- Price
- ADPT $5.08
- MHD $12.14
- Analyst Decision
- ADPT Buy
- MHD
- Analyst Count
- ADPT 4
- MHD 0
- Target Price
- ADPT $6.50
- MHD N/A
- AVG Volume (30 Days)
- ADPT 1.1M
- MHD 124.9K
- Earning Date
- ADPT 11-07-2024
- MHD 01-01-0001
- Dividend Yield
- ADPT N/A
- MHD 4.16%
- EPS Growth
- ADPT N/A
- MHD N/A
- EPS
- ADPT N/A
- MHD N/A
- Revenue
- ADPT $177,282,000.00
- MHD N/A
- Revenue This Year
- ADPT $3.82
- MHD N/A
- Revenue Next Year
- ADPT $20.38
- MHD N/A
- P/E Ratio
- ADPT N/A
- MHD N/A
- Revenue Growth
- ADPT N/A
- MHD N/A
- 52 Week Low
- ADPT $2.28
- MHD $9.92
- 52 Week High
- ADPT $6.70
- MHD $12.18
- Technical
- Relative Strength Index (RSI)
- ADPT 47.04
- MHD 41.88
- Support Level
- ADPT $5.09
- MHD $12.09
- Resistance Level
- ADPT $6.70
- MHD $12.28
- Average True Range (ATR)
- ADPT 0.46
- MHD 0.12
- MACD
- ADPT 0.00
- MHD 0.02
- Stochastic Oscillator
- ADPT 24.48
- MHD 47.14
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About MHD Blackrock MuniHoldings Fund Inc.
Blackrock Muniholdings Fund Inc is a closed-end management investment company. The fund's objective is to provide shareholders with current income exempt from U.S. federal income taxes. The company invests in Transportation, Health, Utilities, Education, Housing, and other sectors.